No abstract

No abstract

The largest sample size to date is the strength of the study and we conclude CD-19 targeted rituximab is a safe and effective agent in the management of adults with SD/CNI dependent MCD/FSGS. At 12 months, over three-fourth of the patients with SD/CNI dependent podocytopathy maintain clinical remission.

Background The role of cigarette smoking as a prognostic factor for kidney cancer (KC) is unclear. In this population‐based study, we analyze cancer‐specific survival (CSS) outcomes among KC patients by smoking status at diagnosis in the diverse state of Florida. Methods All primary KC cases from the Florida Cancer Registry diagnosed during 2005–2018 were analyzed. Cox proportional regression was conducted to assess the determinants of KC survival, including age, sex, race/ethnicity, socioeconomic status, histology type, cancer stage, and treatment received with a particular focus on smoking status (smokers at diagnosis referred to as current smokers, former smokers, and never smokers). Results Among all 36,150 KC patients, 18.3% were smokers at diagnosis (n = 6629), 32.9% were former smokers (n = 11,870), and 48.8% were never smokers (n = 17,651). Age‐standardized five‐year survival for current, former, and never smokers was 65.3 (95% CI: 64.1–66.5), 70.6 (95% CI: 69.7–71.5), and 75.3 (95% CI: 74.6–76.0) respectively. In multivariable analysis, current and former smokers had an estimated 30% and 14% higher risk of KC death compared to never smokers, respectively, after adjusting for potential confounders (HR: 1.30, 95% CI: 1.23–1.40; HR: 1.14, 95% CI: 1.10–1.20). Conclusion Smoking independently contributes to poorer survival, across all KC stages. Clinicians should encourage and facilitate participation in cigarette smoking cessation programs targeted at current smokers. Prospective studies are warranted to assess the role of different types of tobacco use and cessation programs on KC survival.

No abstract

Castration-resistant prostate cancer (CRPC) is fatal and therapeutically under-served. We describe a novel CRPC-restraining role for the vasodilatory soluble guanylyl cyclase (sGC) pathway. We discovered that sGC subunits are dysregulated during CRPC progression and its catalytic product, cyclic GMP (cGMP), is lowered in CRPC patients. Abrogating sGC heterodimer formation in castration-sensitive prostate cancer (CSPC) cells inhibited androgen deprivation (AD)-induced senescence, and promoted castration-resistant tumor growth. We found sGC is oxidatively inactivated in CRPC. Paradoxically, AD restored sGC activity in CRPC cells through redox-protective responses evoked to protect against AD-induced oxidative stress. sGC stimulation via its FDA-approved agonist, riociguat, inhibited castration-resistant growth, and the anti-tumor response correlated with elevated cGMP, indicating on-target sGC activity. Consistent with known sGC function, riociguat improved tumor oxygenation, decreasing the PC stem cell marker, CD44, and enhancing radiation-induced tumor suppression. Our studies thus provide the first evidence for therapeutically targeting sGC via riociguat to treat CRPC.